London-based AI pioneer BenevolentAI Identified a new target for ulcerative colitis through a drug discovery platform.
Candidates were identified by scientists who used BenevolentAI’s target identity tools and machine learning models to identify and experimentally validate new biological targets. Impressively, this achievement was achieved without prior reference in published alliteration or patents relating the gene to ulcerative colitis.
Anne Phelan, Chief Scientific Officer of Benevolent AI, said:
“Ulcerative colitis is a chronic, life-long disease that affects only 0.2% of the U.S. population and 1.6 million patients in seven major markets, but standard treatments provide adequate treatment. I have not received it.
Our new preclinical candidates address the unmet high needs for oral, safe and effective therapies and show improved safety and tolerability profiles compared to other major IBD therapies. I have.
We actively use patient-derived molecular descriptors to target patient subgroups that optimize study design and further increase the chances of success. “
Following candidate identification, BenevolentAI’s molecular design capabilities were used to generate potential oral and peripherally restricted candidate drugs. Preclinical candidates have been experimentally validated with Exvivo ulcerative colitis colon samples from patients who did not respond to current treatment.
Joanna Shields, CEO of Benevolent AI, commented: ”
BenevolentAI plans to put its assets into clinical trials in early 2023.
Learn more about Digital transformation week North America, held November 9-10, 2021, is a virtual event and conference exploring advanced DTX strategies for the world of “Digital Everything”.
https://artificialintelligence-news.com/2021/10/14/benevolentai-drug-discovery-platform-identifies-novel-target-ulcerative-colitis/ BenevolentAI’s drug discovery platform identifies new targets for ulcerative colitis